Open AccessCardiometabolic syndrome: How important is PPARy receptor activation for clinical practice?
Author(s) -
А. В. Барсуков
Publication year - 2008
Publication title -
arterialʹnaâ gipertenziâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-8524
pISSN - 1607-419X
DOI - 10.18705/1607-419x-2008-14-2-116-124
Subject(s) - telmisartan , metabolic syndrome , insulin resistance , medicine , pharmacotherapy , endocrinology , aldosterone , receptor , diabetes mellitus , pharmacology , bioinformatics , biology , blood pressure
Resume Interaction of genetic and environmental factors, metabolic and vascular disturbances increases the risk of total mortality, renal dysfunction, cardiovascular complications. Insulin resistance plays the key role in metabolic syndrome development. Connection of renin-angiotensin-aldosterone system (RAAS) and metabolic risk factors has been carefully studied. Peroxisome proliferator-activated receptors г (PPARг) role in fatty and carbohydrate metabolism is being studied intensively nowadays. Thiazolidinediones impact on cardio-vascular prognosis is controversial, and needs subsequent research. Pleiotropic effects of RAAS-blockers play important role in treatment of high risk patients. Telmisartan, being a partial PPARг-agonist, extends perspective rational pharmacotherapy of hypertension in patients with metabolic syndrome.